Lysophosphatidic acid aberrancies and hepatocellular carcinoma: Studies in the MDR2 gene knockout mouse

Nicholas Skill, Jianmin Wu, Yan Xu, Zheng Zhao, Mary Maluccio

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Studies show that lysophosphatidic acid (LPA) reprogramming is associated with the development of hepatocellular carcinoma (HCC). This manuscript evaluates the MDR2-/- model of HCC as a tool to examine the role of LPA reprogramming in the initiation/progression of HCC and identify novel treatment targets. Hepatic tumors developed in MDR2-/- mice between 9-12 m and serum LPA levels were greater in MDR2-/- when compared to controls. Blocking LPA biosynthesis/signaling significantly reduced tumor burden. LPA biosynthesis/signaling plays an important role in murine MDR2 -/- model and is potentially linked to regulation of TNFα or other cytokines that are relevant to high-risk patients.

Original languageEnglish (US)
Pages (from-to)145-155
Number of pages11
JournalCancer Investigation
Volume31
Issue number2
DOIs
StatePublished - Feb 1 2013

Keywords

  • CAMP
  • HCC
  • Multiple Drug Resistance Gene
  • TNF Alpha

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Lysophosphatidic acid aberrancies and hepatocellular carcinoma: Studies in the MDR2 gene knockout mouse'. Together they form a unique fingerprint.

  • Cite this